← Back to Search

Fixed-Ratio Combination Therapy

IDegLira for Diabetes

Phase 3
Waitlist Available
Led By Rodolfo Galindo, MD
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week1, week 12, week 26
Awards & highlights

Study Summary

This study is evaluating whether a new combination of insulin and a medication called liraglutide may help improve blood sugar control in patients with poorly controlled type 2 diabetes. original

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week1, week 12, week 26
This trial's timeline: 3 weeks for screening, Varies for treatment, and week1, week 12, week 26 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Hemoglobin A1c (HbA1c)
Secondary outcome measures
Asymptomatic Hypoglycemic Events
Average Daily Blood Glucose
Average Fasting Blood Glucose
+22 more

Side effects data

From 2022 Phase 3 trial • 145 Patients • NCT03737240
38%
Nausea
19%
Emergency Room Visits
18%
Abdominal Pain
13%
Vomiting
11%
Diarrhea
100%
80%
60%
40%
20%
0%
Study treatment Arm
IDegLira
Basal-Bolus Insulin

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: IDegLiraExperimental Treatment1 Intervention
Participants in this group will receive IDegLira (with metformin, unless contraindicated) for 26 weeks.
Group II: Basal-Bolus InsulinActive Control2 Interventions
Participants in this group will receive basal-bolus insulin (with metformin, unless contraindicated) for 26 weeks. The basal-bolus insulin regimen includes Insulin Degludec (U-100) and Insulin Aspart.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
IDegLira
2021
Completed Phase 4
~1020

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,639 Previous Clinical Trials
2,560,501 Total Patients Enrolled
32 Trials studying Diabetes
16,846 Patients Enrolled for Diabetes
Novo Nordisk A/SIndustry Sponsor
1,514 Previous Clinical Trials
2,414,923 Total Patients Enrolled
646 Trials studying Diabetes
756,738 Patients Enrolled for Diabetes
Rodolfo Galindo, MDPrincipal Investigator - Emory University
Emory University
1 Previous Clinical Trials
64 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
IDegLira HIGH Trial
Rodolfo Galindo 2019. "IDegLira HIGH Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03737240.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top